Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Albumin-bound paclitaxel + carboplatin is a combination chemotherapy regimen being evaluated by Sun Yat-sen University for the treatment of cervical cancer. The regimen is the focus of the Phase 3 N6C trial, which investigates its efficacy and safety as neoadjuvant chemotherapy followed by chemoradiation in patients with stage IIIC cervical cancer. Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that utilizes nanoparticle technology to improve drug delivery to tumors while minimizing hypersensitivity reactions. Carboplatin is a platinum-based cytotoxic agent that induces DNA damage through the formation of cross-links. This combination aims to improve clinical outcomes by reducing tumor burden and targeting systemic disease prior to definitive local therapy.
- Brand names
- AbraxaneParaplatin
- Other names
- nab-paclitaxel + carboplatinnanoparticle albumin-bound paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))SPARC (Secreted protein acidic and rich in cysteine)DNAgp60 (GP60 Receptor)
Beyond the preview
Go deeper on albumin-bound paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + carboplatin.